Molecular Formula | C22H28F2O5 |
Molar Mass | 410.45 |
Density | 1.1621 (estimate) |
Melting Point | 237-240°C |
Boling Point | 569.8±50.0 °C(Predicted) |
Specific Rotation(α) | [α]25/D 67.0 to 71.0°, c = 1 in dioxane |
Flash Point | 298.4°C |
Water Solubility | 1mg/L(20 ºC) |
Solubility | Slightly soluble in ethanol, slightly soluble in chloroform, methanol, very slightly soluble in ether, almost insoluble in water. DMSO 82 mg/mL;Water <1 mg/mL;Ethanol 6 mg/mL. |
Vapor Presure | 2.33E-15mmHg at 25°C |
Appearance | White to Off-White Solid |
Color | white |
Merck | 14,4138 |
pKa | 11.98±0.70(Predicted) |
Storage Condition | 2-8°C |
Refractive Index | 1.579 |
MDL | MFCD00056464 |
In vivo study | Treatment of calves with fluethasone (0.5 mg/100kg body weight) for 24 hours decreased insulin-dependent glucose utilization. The combination of fluethasone and Sodium ceftiofur in calves with severe acute bronchopneumonia reduced mortality and clinical and hematological parameters and returned to normal levels significantly faster than control calves. Fluethasone (5 mg) had a significant effect on the recovery of uterine disease in calves with ketosis. Fluethasone (5 mg), treated calves with ketosis, increased plasma glucose concentrations and decreased serum β-hydroxybutyrate and urinary acetoacetate concentrations. While fluethasone levels in experimental animals were generally above the detection limit in most cases, fluethasone concentrations in Dexamethasone-treated calves were lower than the corresponding glucocorticoid levels. Fluethasone can also be detected in calf urine samples. Fluethasone binds to plasma corticotroponin and is an activated state when it is not bound to corticotroponin. |
Hazard Symbols | Xn - Harmful |
Risk Codes | 40 - Limited evidence of a carcinogenic effect |
Safety Description | S22 - Do not breathe dust. S36 - Wear suitable protective clothing. |
WGK Germany | 3 |
RTECS | TU3832000 |
HS Code | 29144000 |